Stepping up its myopia suite, Carl Zeiss Vision International is acquiring Brighten Optix, a Taipei-based “leading player” in the field of orthokeratology (ortho-k) and specialty contact lenses.
Zeiss is proud of its spectacle lens portfolio – clinically proven to slow the progression of myopia – but recognises the need to offer more options to its partners to protect and improve the vision of many more children, said Sven Hermann, Zeiss Vision Care CEO and Zeiss’ executive board member. “Brighten Optix products are widely available and used by eyecare professionals in Greater China and across Southeast Asia. Their proven and innovative portfolio of specialty contact lenses will complement Zeiss Vision Care’s existing myopia control offerings.”
Brighten Optix is known for its commitment to research and development, Hermann said. “With Zeiss’ heritage of leading innovation, I am confident this common strength will be of even greater advantage in our joint future.”
The acquisition is expected to close early 2026. It remains subject to completion of conditions and regulatory approvals.
